Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

456.17 -9.17 (-1.97%)

Streaming Delayed Price Updated: 12:25 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Alnylam Completes Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy

June 01, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentations at Upcoming June Investor Conferences

May 26, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces New Advances in ATTR Amyloidosis Program

May 11, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentations at Upcoming May Investor Conferences

May 04, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)

May 03, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals Inc (ALNY) Q1 2021 Earnings Call Transcript ↗

April 29, 2021

ALNY earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Alnylam Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity

April 29, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx ↗

April 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...

Via Benzinga

Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran

April 19, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx ↗

April 24, 2021

Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:...

Via Benzinga

The Week Ahead In Biotech: Johnson & Johnson, Biogen Earnings, Neurology Conference And IPOs ↗

April 17, 2021

The FDA and CDC announced their recommendation to pause the use of Johnson & Johnson's JNJ COVID-19 vaccine following incidences of severe clots. J&J's pain turned into gains for other COVID-19 vaccine...

Via Talk Markets

The Week Ahead In Biotech: Johnson & Johnson, Biogen Earnings, Neurology Conference And IPOs ↗

April 17, 2021

Biotech stocks reversed course in the week ended April 16, with the sector rebounding along with the broader market. The week's news flow was fairly light. The American...

Via Benzinga

Alnylam to Webcast Conference Call Discussing First Quarter 2021 Financial Results

April 15, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Presents Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension

April 11, 2021

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Dicerna Sells Oxlumo Royalty Interest To Royalty Pharma For $180M Upfront ↗

April 08, 2021

Royalty Pharma plc (NASDAQ: RPRX) has acquired Dicerna Pharmaceuticals Inc's (NASDAQ: DRNA) royalty interest in Oxlumo (lumasiran) for an...

Via Benzinga

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.